Your browser doesn't support javascript.
loading
Metabolic signature and response to glutamine deprivation are independent of p53 status in B cell malignancies.
Montironi, Chiara; Chen, Zhenghao; Derks, Ingrid A M; Cretenet, Gaspard; Krap, Esmée A; Eldering, Eric; Simon-Molas, Helga.
Afiliación
  • Montironi C; Amsterdam UMC Location University of Amsterdam, Department of Experimental Immunology, Amsterdam, the Netherlands.
  • Chen Z; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.
  • Derks IAM; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, the Netherlands.
  • Cretenet G; Amsterdam UMC Location University of Amsterdam, Department of Experimental Immunology, Amsterdam, the Netherlands.
  • Krap EA; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.
  • Eldering E; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, the Netherlands.
  • Simon-Molas H; Amsterdam UMC Location University of Amsterdam, Department of Experimental Immunology, Amsterdam, the Netherlands.
iScience ; 27(5): 109640, 2024 May 17.
Article en En | MEDLINE | ID: mdl-38680661
ABSTRACT
The tumor suppressor p53 has been described to control various aspects of metabolic reprogramming in solid tumors, but in B cell malignancies that role is as yet unknown. We generated pairs of p53 functional and knockout (KO) clones from distinct B cell malignancies (acute lymphoblastic leukemia, chronic lymphocytic leukemia, diffuse large B cell lymphoma, and multiple myeloma). Metabolomics and isotope tracing showed that p53 loss did not drive a common metabolic signature. Instead, cell lines segregated according to cell of origin. Next, we focused on glutamine as a crucial energy source in the B cell tumor microenvironment. In both TP53 wild-type and KO cells, glutamine deprivation induced cell death through the integrated stress response, via CHOP/ATF4. Lastly, combining BH3 mimetic drugs with glutamine starvation emerged as a possibility to target resistant clones. In conclusion, our analyses do not support a common metabolic signature of p53 deficiency in B cell malignancies and suggest therapeutic options for exploration based on glutamine dependency.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IScience Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IScience Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos
...